Cerebrolysin treatment

PreclinicalSmall molecule

UUniversity Medical Centre Ljubljana

Cerebrolysin treatment is one of 42 small molecule programs targeting Stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Keppra

UCB

Phase 3

2 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Zantac 150

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Stroke

NCT07043686

Clinical

Trials by Indication[1]

Stroke1 trial

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT07043686·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cerebrolysin treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cerebrolysin treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cerebrolysin treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Centre Ljubljana company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Medical Centre Ljubljana

Cerebrolysin treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Stroke1 trial

References

Drug Info

Quick Facts

Related News